Tuesday, June 1

7:00-8:10AM
Welcoming Remarks and Keynote Session (Joint) (7am Denver/Mountain Time Start)
*Persephone Borrow, University of Oxford, UK
*Carine M. Van Lint, University of Brussels, Belgium
M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Accelerating HIV Vaccine Development to Prevent HIV Infection
Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
I Am Nothing Without You: The Rationale for T Cell Plus B Cell Vaccines for HIV

8:10-9:45AM
Breakthrough Technologies (Joint) (8:10am Denver/Mountain Time Start)
*Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
*M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Michael R. Betts, University of Pennsylvania, USA
Mark M. Davis, Stanford University School of Medicine, USA
Guillaume J. Filion, University of Toronto Scarborough, Canada
What Have We Learned from HIV-Barcoding Technologies?
Collin Kieffer, University of Illinois at Urbana-Champaign, USA
Short Talk: Spatial Profiling of HIV-1 Transmission in Lymphoid Tissues from Humanized Mice and Human Patients with Single-Cell to Single-Virus Resolution
Fredrick Kizito, Case Western Reserve University, USA
Short Talk: Visualization of HIV Integration and Latency by CasFISH: In situ Imaging System for Localization of the Provirus and its Transcriptional Regulators in Infected Cells
Matthew Osborn, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Evolutionary Dynamics of HIV-1 Reservoir Cells Revealed by a Novel Multi-Dimensional Single-Cell Assay

10:05AM-12:00PM
Insights from Preclinical and Clinical Trials (10:05am Denver/Mountain Time Start)
*M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
*Barton F. Haynes, Duke University Medical Center, USA
Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
AMP Trial Results
Sandhya Vasan, US Military HIV Research Program, USA
Optimizing Adjuvants for Clinical Vaccine Development
William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Human Clinical Test of Germline Targeting: Preliminary Report on B-Cell Responses in the IAVI G001 Trial of eOD-GT8 60mer
Robin Shattock, Imperial College London, UK
Accelerated Experimental Medicine Trials for Iterative Vaccine Design
Marie-Claire E. Gauduin, Texas Biomedical Research Institute, USA
Short Talk: Efficacy of a Novel Epithelial Stem Cell-based AIDS Vaccine to Induce Mucosal Immune Responses and Control SIV Transmission in Macaques

1:00-2:00PM
Career Roundtable (Joint) (1pm Denver/Mountain Time Start)
Devi SenGupta, Gilead Sciences, Inc., USA
Kevin O. Saunders, Duke University, USA

Wednesday, June 2

7:00-9:25AM
Immunogen Design for Broadly Neutralizing Antibody Induction (7am Denver/Mountain Time Start)
*William Schief †, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
*Darrell J. Irvine †, Massachusetts Institute of Technology, USA
**9:45AM-12:00PM**

**Inducing/Modulating Antibody Effector Functions (9:45am Denver/Mountain Time Start)**

*Georgia D. Tomaras*, Duke University Medical Center, USA

*Jay A. Berzofsky*, NCI, National Institutes of Health, USA

**Hugo Mouquet**, Institut Pasteur, France

Broadly HIV-1 Neutralizing IgA Antibodies

**Margaret E. Ackerman**, Dartmouth College, USA

Optimizing Antibodies for Antiviral Activity in vivo

**Rasmi Thomas**, U.S. Military HIV Research Program, USA

Single Cell Technologies Indicate Monocyte Expression Profiles Influence HIV Reservoir Size and Vaccine Efficacy

**Meredith Phelps**, Harvard University, USA

Short Talk: Broadly Neutralizing Antibody Recognition of HIV Envelope Epitopes Modulates Effector Function

**Maria Victoria Filsinger Interrante**, Stanford University, USA

Short Talk: The High-affinity Immunoglobulin Receptor FcγRI Potentiates HIV-1 Neutralization via Antibodies against the gp41 N-heptad Repeat: Implications for Vaccine Development

**Marc Ehlers**, University of Luebeck, Germany

Short Talk: IgG Fc Sialylation is Regulated during the Germinal Center Reaction Following Immunization with Different Adjuvants

**Rebekah T. Sherburn**, Uniformed Services University of the Health Sciences, USA

Short Talk: Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of HIV-1 Envelope to Elicit Cross-Clade Response with Potent Fc-effector Functions

---

**1:00-2:30PM**

**Poster Session 1 (Joint) (1pm Denver/Mountain Time Start)**

**Meet the Editors (Joint) (2:30pm Denver/Mountain Time Start)**

**Montserrat Cols-Vidal**, Journal of Experimental Medicine, USA

**Zeljko Durdevic**, EMBO Press, Germany

**Sara Hamilton**, Cell Press, USA

**Alison Farrell**, Springer Nature, USA

---

**Thursday, June 3**

**7:00-9:25AM**

**Optimizing Germinal Center Responses for Broadly Neutralizing Antibody Induction (7am Denver/Mountain Time Start)**

*Rogier W. Sanders*, University of Amsterdam and Weill Cornell Medical College, Netherlands

*Kevin O. Saunders*, Duke University, USA

**Michel C. Nussenzweig**, HHMI/Rockefeller University, USA

GC Regulation Learning from Mice and Men

**Persephone Borrow**, University of Oxford, UK

Exploiting the Immunological Environment Supporting HIV-1 BnAb Induction During Infection to Inform Vaccine Design
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Designing Immunization Regimens to Promote the Germinal Center Response

Facundo D. Batista, Massachusetts Institute of Technology and Harvard University, USA
Targeting HIV-1 ENV V2-apex bNAb Precursors in Human Ig Knock-in Mouse Models

Jacob K. Files, University of Alabama Birmingham, USA
Short Talk: HLA-II Associated Viral Adaptation Impacts the Quantity and Quality of CD4+ T-Cell Responses in HIV-1 Vaccine Recipients

Amelia Escolano, Rockefeller University, USA
Short Talk: Sequential Immunization Strategies To Elicit Anti HIV-1 Broadly Neutralizing Antibodies

Angela Corrigan, NIAID, National Institutes of Health, USA
Short Talk: Fusion Peptide Priming and Long Trimer Interval Reduces Off-target Antibody Responses Toward the HIV-1 Trimer Base Region

9:45-11:25AM
CD8 T Cell Inducing Vaccines (9:45am Denver/Mountain Time Start)

*Persephone Borrow, University of Oxford, UK

*Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA

Louis J. Picker, Oregon Health & Science University, USA
Latest Developments in CMV-Vectored HIV/SIV Vaccines

Andrew J. McMichael, Oxford University, UK
Understanding HLA-E Mediated Antigen Presentation to Inform Vaccine Design

Bette Korber, Los Alamos National Laboratory, USA
Design of Vaccines to Elicit Conventional (La)-restricted CD8 T Cell Responses

Michael R. Betts, University of Pennsylvania, USA
CD8+ T Cell Tissue Recirculation and Residency in HIV Infection

1:00-2:30PM
Poster Session 2 (Joint) (1pm Denver/Mountain Time Start)

Friday, June 4
7:00-9:50AM
Therapeutic Vaccines (Joint) (7am Denver/Mountain Time Start)

*Andrew J. McMichael, Oxford University, UK

*Bonnie J. Howell, Merck & Co., Inc., USA

Barbara K. Felber, NCI, National Institutes of Health, USA
Therapeutic Vaccines – Preclinical to Clinical Trials

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Therapeutic Antibody and Vaccine Strategies

Julie Ake, Walter Reed Army Institute of Research, USA
HIV Remission in Acutely Treated Populations

Brad Jones, Weill Cornell Medicine, USA
Target-Intrinsic CTL Resistance, A Role in Reservoir Persistence?

Beatriz Mothe, IrsiCaixa AIDS Research Institute-HIVACAT, Spain
AEIX-002: A RCT with HTI Therapeutic Vaccines in Early-Treated HIV

Leonard Mvaya, Malawi-Liverpool Wellcome Trust Clinical Research Programme, Malawi
Short Talk: Duodenal Tissue-Resident CD8+ T Cells Exhibit Low Cytolytic Molecule Expression and Spatially Localise Away from HIV-Susceptible CD4+ T Cells

Amit Kumar Singh, National Institute for Research in Reproductive Health, India
Short Talk: Non-Cytotoxic Signatures Dominate HIV Specific T Cell Responses in Viremic Non-Progression

Deanna A. Kulp, Emory University, USA
Short Talk: The Contribution of CD8+ T Lymphocytes to HIV/SIV Persistence during ART

10:10-11:40AM
Considerations in Future Vaccine Design (10:10am Denver/Mountain Time Start)

*Sandhya Vasan, US Military HIV Research Program, USA

*Georgia D. Tomaras, Duke University Medical Center, USA

Keith Reeves, Duke University School of Medicine, USA
HIV-Specific NK Cells Responses and their Potential for Harnessing in Vaccine Design

Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa
Innate Immune Signatures Associated with HIV Vaccine Immunogenicity
Nichole R. Klatt, University of Minnesota, USA  
Potential Role of the Microbiome in HIV Vaccination

Ashley N. Nelson, Duke University, USA  
Short Talk: Induction of Neutralizing Antibody Responses in BG505 SOSIP Immunized Infant Rhesus Macaques

11:40-11:50AM    Closing Remarks (11:40am Denver/Mountain Time Start)
12:00-1:00PM    Networking Lounge (Joint) (12pm Denver/Mountain Time Start)